Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia

Starting soon

Conditions studied: X-linked Hypophosphatemia (XLH)

In brief

The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XLH-related conditions.

Key facts

Study ID

NCT07607600

Run by

Novo Nordisk A/S

People needed

100

Starts

2026-07-07

Expected to finish

2030-07-07

Last updated by the study team

2026-05-26

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent obtained before any trial-related activities, i.e., any procedure related to recording of data according to the protocol.
• Male or female and aged 18-64 years (both inclusive) at the time of signing informed consent.
• Diagnosis of congenital XLH, confirmed genetically or clinically as determined by the investigator, supported by documentation.
• Participants have been treated with burosumab for at least 90 days prior to the screening/baseline visit and treatment is still ongoing.
• Participant confirms ability and willingness to attend visits according to routine clinical care and mandatory assessments at the site.

You may not qualify if…

• Previous rescreening for this trial.
• Current participation in any interventional clinical trial. Participation in another non-interventional trial, such as a patient registry trial, is permitted.
• Any condition not associated with XLH, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States
• Indiana University Hospital — Indianapolis, Indiana, United States
• The Ohio State University Wexner Medical Center (OSUWMC) - CarePoint East — Columbus, Ohio, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Northern Sydney Cancer Centre-Royal North Shore Hospital (RNSH) — St Leonards, New South Wales, Australia
• Westmead Hospital — Westmead, New South Wales, Australia
• Monash University - Monash Medical Centre (MMC) — Clayton, Victoria, Australia
• Bone Research and Education Centre — Oakville, Ontario, Canada
• CHU de Bicetre — Le Kremlin, France
• Hopital Cochin - APHP — Paris, France
• Charite Campus Virchow — Berlin, Germany
• Endokrinologikum Goettingen — Göttingen, Germany
• Universitat Wurzburg Koenig-Ludwig-Haus — Wuezburg, Germany
• Office of Francesco Di Costanzo, MD — Sesto Fiorentino, Florence, Italy
• Istituto Auxologico Italiano — Milan, Italy
• Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia — Padova, Italy
• Fondazione Policlinico Universitario Campus Bio-Medico — Rome, Italy
• Fukuoka University - Fukuoka University Hospital — Fukuoka, Fukuoka, Japan
• Okayama Saiseikai Outpatient Center Hospital — Okayama, Okayama-ken, Japan
• The University of Tokyo Hospital — Bunkyo-ku, Tokyo, Japan
• Iseikai International General Hospital — Osaka, Japan
• Japan Community Healthcare Organization Osaka Hospital — Osaka, Japan
• Leiden University Medical Center (Leids Universitair Medisch Centrum (LUMC)) — Leiden, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.